89bio, Inc. (ETNB) |
|
20.45 0.46 (2.3%)
|
06-06 16:00 |
|
Open: |
19.97 |
Pre. Close: |
19.99 |
|
High:
|
20.85 |
Low:
|
19.28 |
|
Volume:
|
1,473,247 |
Market Cap:
|
1,490(M) |
|
|
|
Technical analysis |
as of: 2023-06-06 3:49:06 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
|
| Target: |
Six months: 24.35  One year: 28.44 |
| Support: |
Support1: 17.5 Support2: 15.44 |
| Resistance: |
Resistance1: 20.85 Resistance2: 24.35 |
| Pivot: |
17.84 |
| Moving Average: |
MA(5): 19.27 MA(20): 17.85
MA(100): 14.8 MA(250): 9.84 |
| MACD: |
MACD(12,26): 0.8 Signal(9): 0.5 |
| Stochastic oscillator: |
%K(14,3): 92.5  %D(3): 91.1 |
| RSI: |
RSI(14): 71 |
| 52-week: |
High: 20.85 Low: 2.91 |
| Average Vol(K): |
3-Month: 2,301 (K) 10-Days: 1,255 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ETNB ] has closed above the upper band by 3.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 30.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
20.13 - 20.2 |
20.2 - 20.27 |
|
Low:
|
18.62 - 18.7 |
18.7 - 18.78 |
|
Close:
|
19.85 - 19.97 |
19.97 - 20.09 |
|
Company Description |
|
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California. |
Headline News |
Tue, 06 Jun 2023
89bio Inc (ETNB) Stock Is Higher By 16.84% This Week: Buy, Hold, or Sell? - InvestorsObserver
Tue, 06 Jun 2023
89bio, Inc. (NASDAQ:ETNB) Director Edward Morrow Atkinson III ... - Defense World
Tue, 06 Jun 2023
89bio, Inc. (NASDAQ:ETNB) Receives Consensus Rating of "Buy ... - MarketBeat
Mon, 29 May 2023
Validea's Top 5 Health Care Stocks Based On Warren Buffett - 5/29 ... - Nasdaq
Sun, 28 May 2023
Raymond James Financial Services Advisors Inc. Sells 57417 ... - MarketBeat
Wed, 24 May 2023
Will 89bio Inc (ETNB) Stay at the Top of the Healthcare Sector? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
73 (M) |
| Shares Float |
61 (M) |
|
% Held by Insiders
|
0.6 (%) |
|
% Held by Institutions
|
68.7 (%) |
|
Shares Short
|
7,220 (K) |
|
Shares Short P.Month
|
7,640 (K) |
Stock Financials |
|
EPS
|
-2.3 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
6.11 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-21 |
|
Return on Equity (ttm)
|
-38.4 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.45 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-87 (M) |
|
Levered Free Cash Flow
|
-49 (M) |
Stock Valuations |
|
PE Ratio
|
-8.84 |
|
PEG Ratio
|
-0.9 |
|
Price to Book value
|
3.31 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-17.05 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
